PVSRIPO and Pembrolizumab in Patients With Recurrent Glioblastoma

lady with scarf
AGE: 18 years and older
TYPE: Biological Study (PVSRIPO, pembrolizumab)
CONDITION: Glioblastoma, Recurrent Glioblastoma, Supratentorial Glioblastoma, Brain Tumor

ISTR1320, A Phase 1, Open-label, Single-arm Study Evaluating the Safety and Tolerability of Oncolytic Polio/Rhinovirus Recombinant (PVSRIPO) and the Immune Checkpoint Inhibitor Pembrolizumab in the Treatment of Patients with Recurrent Glioblastoma (PVSRIPO CPI rGBM 101)

Study Purpose

The purpose of this study is to determine the tolerance, safety and efficacy of a single dose of PVSRIPO followed by pembrolizumab is in adults diagnosed with a recurrent glioblastoma (rGBM). PVSRIPO and Pembrolizumab are investigational (experimental) drugs. Pembrolizumab works by helping your immune system recognize and fight cancer cells.

Who Can Participate

Patients 18 years of age or older 18 years of age who have been histologically confirmed with recurrent, supratentorial glioblastoma; progression of primary glioblastoma or transformation from a lower grade to a higher grade of glioblastoma may be eligible for this study.

Learn More About This Research Study

For more information, please call 1-800-641-2422 or contact us using the online form below.

To learn more about this study, please fill out the form below to request more information.

Study ID

Principal Investigator: Andrew Sloan, MD

Andrew Sloan 500x600